EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PANoptosis in the pathogenesis of myelodysplastic syndromes

Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang iD

Molecular Oncology · 2026-11 · 20 (11) · 2584-2610

DOI: 10.1002/1878-0261.70309 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Oncology, online erschienen am 24.07.2026. Verfasst von Rohit Thalla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago Medical Center, Maywood, IL, USA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Apoptosis, Necroptosis. Die Arbeit nennt 283 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Division of Cancer Prevention, National Cancer Institute, NHLBI NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelodysplastic syndromes (MDS) are a heterogeneous group of pre‐leukemic diseases marked by ineffective bone marrow (BM) hematopoiesis, peripheral cytopenia, morphologic dysplasia, and an increased risk of leukemic transformation. Increased programmed cell death (PCD) of hematopoietic stem/progenitor cells (HSPCs) and its associated inflammatory BM microenvironment have been speculated to be one of the major causes of ineffective hematopoiesis. PANoptosis is a collective term for three types of PCD: pyroptosis, apoptosis, and necroptosis. All three are mediated by a very large protein complex called a PANoptosome, composed of the key mediators of the three types of PCD. We reported that the diseased cells in MDS with genetic abnormalities, especially spliceosome mutations, show aberrant hypersensitivity to PANoptotic stimuli. Our study suggests that increased PANoptosis of BM HSPCs is one of the reasons for the ineffective hematopoiesis in MDS patients, and targeting PANoptosis may be a novel treatment strategy for MDS. Here we summarize recent advances in research into PANoptosis and discuss the potential role of PANoptosis in the pathogenesis of MDS. We discuss the potential mechanisms for targeting PANoptotic pathways to treat MDS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesApoptosisNecroptosisHumansAnimalsHematopoietic Stem CellsHematopoiesis

Stichwörter der Autor:innen

PANoptosisRipk1Tak1caspase 8ineffective hematopoiesis

Autor:innen und Institutionen

  • Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago Medical Center, Maywood, IL, USA.
  • Department of Cancer Biology, Loyola University Chicago Medical Center, Maywood, IL, USA.
  • Departments of Biology and Molecular/Cellular Physiology, Loyola University Chicago, Maywood, IL, USA.

ORCID-Profile: Jiwang Zhang

Förderung

  • Division of Cancer Prevention, National Cancer Institute
  • NHLBI NIH HHS
  • NCI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Thalla, R., Lamichhane, J., Lewis, C., Breslin, P., & Zhang, J. (2026). PANoptosis in the pathogenesis of myelodysplastic syndromes. Molecular Oncology, 20(11), 2584-2610. https://doi.org/10.1002/1878-0261.70309

Vancouver

Thalla R, Lamichhane J, Lewis C, Breslin P, Zhang J. PANoptosis in the pathogenesis of myelodysplastic syndromes. Molecular Oncology. 2026;20(11):2584-2610. doi:10.1002/1878-0261.70309

BibTeX
@article{Thalla2026,
  author = {Thalla, Rohit and Lamichhane, Jyoti and Lewis, Cameron and Breslin, Peter and Zhang, Jiwang},
  title = {PANoptosis in the pathogenesis of myelodysplastic syndromes},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {11},
  pages = {2584--2610},
  doi = {10.1002/1878-0261.70309}
}
Kostenlos starten →